In multivariable analysis, EZH2 was also an independent prognostic marker for OS (T-NHL: HR = 8.245; 95% CI: 1.898–35.826; p = 0.005; nodal T-NHL: HR = 28.398; 95% CI: 2.166–372.334; p = 0.011) and PFS (T-NHL: HR = 3.754; 95% CI: 1.233–11.426; p = 0.020; nodal T-NHL: HR = 5.147; 95% CI: 1.472–17.998; p = 0.010). Here, EZH2 is linked to non-Hodgkin lymphoma.